**Practical recommendations for diagnostic accuracy studies in low prevalence situations**

Gea A. Holtman[a,b], Marjolein Y. Berger[b], Huibert Burger[b], Jonathan J. Deeks[c], Norbert Donner-Banzhoff[d], Thomas R. Fanshawe[a], Constantinos Koshiaris[a], Mariska M. Leeflang[e], Jason L. Oke[a], Rafael Perera[a], Johannes B. Reitsma[f], Ann Van den Bruel[a,g]


[a] Nuffield Department of Primary Care Health Sciences, Radcliffe Observatory Quarter, University of Oxford, Oxford OX2 6GG, UK

[b] Department of General Practice and Elderly Care Medicine, University Medical Centre Groningen, University of Groningen, PO Box 196, 9700 AD Groningen, the Netherlands

[c] Institute of Applied Health Research, University of Birmingham, Birmingham B15 2TT, UK

[d] Department of General Practice and Family Medicine, Faculty of Medicine, Philipps University of Marburg, Karl-von-Str. 4, Marburg 35037, Germany

[e] Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, University of Amsterdam, PO Box 22700, 1100 DE Amsterdam, the Netherlands

[f] Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, the Netherlands

[g] Academic Centre of General Practice, University of Leuven, Kapucijnenvoer 33 blok J, Belgium


**Corresponding author:** G.A. Holtman, Department of General Practice and Elderly Care Medicine, University Medical Centre Groningen, University of Groningen, PO Box 196, 9700 AD Groningen, the Netherlands. Telephone: 0031 642637125 E-mail address: g.a.holtman@umcg.nl

**Abstract**

**Objective:** Low disease prevalence poses challenges for diagnostic accuracy studies because of the large sample sizes that are required in order to obtain sufficient precision. The aim is to collate and discuss designs of diagnostic accuracy studies suited for use in low prevalence situations.

**Study design and setting:** We conducted a literature search including backward citation tracking and expert consultation. Two reviewers independently selected studies on designs for estimating diagnostic accuracy in a low prevalence situation. During a one-day expert meeting, all designs were discussed and recommendations were formulated.

**Results:** We identified six designs for diagnostic accuracy studies that are suitable in low prevalence situations, because they reduced the total sample size or the number of patients undergoing the index test or reference standard depending on which poses the highest burden. We described the advantages and limitations of these designs and evaluated efficiencies in sample sizes, risk of bias and alignment with the clinical pathway for applicability in routine care.

**Conclusion:** Choosing a study design for diagnostic accuracy studies in low prevalence situations should depend on whether the aim is to limit the number of patients undergoing the index test or reference standard, and the risk of bias associated with a particular design type.

**What is new?**

- An overview of study designs or methods that could be used for diagnostic accuracy studies in low disease prevalence situations is lacking
- We present a general guide for choosing the most suitable design in different low disease prevalence situations
- Suggestions for computing confidence intervals, weighted analysis, sample size calculations, binary logistic regression analysis and population weighting is provided
- The advantages and limitations of using routine healthcare data for diagnostic accuracy studies are discussed

## 1. Introduction

A low prevalence situation occurs when in a group of patients suspected of a particular disease or target condition, only a few will actually have the disease in question. For example, about 1 in 170 adults who present with persistent cough in primary care will have lung cancer [1], and 1 in 125 children with an acute illness in primary care will have a serious infection [2]. This situation is quite common in primary care, but can also occur in screening situations or when diagnosing rare diseases in secondary and tertiary care.

The classic design for estimating diagnostic accuracy is a cross-sectional cohort study recruiting consecutive patients suspected of the target condition who subsequently receive the index test and the reference standard (Fig. 1A). Figure 2 shows that the challenge in low prevalence situations is that a classic design requires very large sample sizes in order to estimate sensitivity with sufficient precision in diseased patients and consequently to calculate other measures that involve the diseased group, e.g. likelihood ratios and predictive values. For example, the prevalence of inflammatory bowel disease in children with chronic gastrointestinal symptoms presenting to primary care is around 1% [3,4], such that only 61 cases would be expected in a cohort of 6146 children. If 49 of these 61 cases were index test positive, the estimated sensitivity of 80% would have a confidence interval ranging from 70% to 90% [5]. Such studies are not only logistically difficult to achieve, but also subject a large group of patients to both the index test and reference standard, raising ethical and financial issues depending on their level of invasiveness and costs.

Consequently, diagnostic accuracy studies in low prevalence situations either include so few diseased patients producing imprecise estimates of diagnostic accuracy parameters, or are so large that they risk being undeliverable and unaffordable. Uncertainty of the value of diagnostic tests in low prevalence situations hampers routine practice, particularly in primary care where important conditions appear at low prevalence within the large population of healthcare contacts [6]. Study designs or methods that require smaller sample sizes and are therefore less challenging, yet yield unbiased and sufficiently precise estimates of test accuracy are thus highly desirable. To the best of

our knowledge, an overview listing all available study designs and methods does not exist. The aim of this paper is to identify and discuss designs and methods of diagnostic accuracy studies that can be used in low prevalence situations.

## 2. Methods

### 2.1. Search Strategy

A literature search to identify relevant methods was conducted in the Cochrane Library, Embase, Medline, and Web of Science databases from inception until 14 July 2017. For the search strategies see Appendix 1. Additionally, invited experts in the area of diagnostic research reviewed the list of selected studies to identify any omissions and provide suggestions for other methods or study designs not covered by the literature review. Finally, we performed backward citation tracking on Scopus and Web of Science of all included studies. No language restrictions were applied.

### 2.2 Study selection

Two reviewers (AVdB and GAH) independently selected eligible studies. We included all studies describing a specific study design or method for estimating diagnostic accuracy in a low prevalence situation. Low prevalence was defined as a maximum of 10% of the suspected population with the target condition. Studies on prognostic tests or impact studies of diagnostic tests were excluded, but screening studies included. Studies were selected on title and abstract first and on full-text articles thereafter. Disagreement between reviewers was resolved by discussion.

### 2.3. Evaluating methods

Data were extracted by one reviewer (GAH) in a predefined extraction sheet. We invited a group of European experts in the area of diagnostic research in low prevalence situations with varying

expertise, i.e. clinical, methodological, or statistical expertise. During a one-day meeting with the experts the identified designs and methods were discussed with regards to their advantages and limitations, and recommendations were formulated. In particular, we looked at efficiencies in sample sizes, risks of bias and alignment with the routine clinical pathway for applicability in routine care. Additionally, we discussed considerations that could help choosing the most suitable design in different low prevalence situations: depending on whether patient selection, the burden associated with index test or reference standard, or the target condition itself poses the largest problem, one design may be more suitable than another. We made a general guide taking into account the main risks of bias according to the QUADAS-2, the quality assessment tool for diagnostic accuracy studies [7,8].

### 3. Results

The literature search, expert input and backward citation tracking yielded 16 studies (Appendix 2). All studies and their details are shown in Appendix 3. We categorized the identified methods in the following sections: designs, analytic considerations, and using routine healthcare data. We identified six designs that are particularly efficient for diagnostic test evaluation in low prevalence situations (Figure 1). Table 1 provides an example of each design. In appendix 4, we comment on analytical considerations such as sample size calculations, computing confidence intervals, weighted analysis, binary logistic regression, and population weighting in these situations.

### 3.1. Designs

### 3.1.1. Design decreasing the total sample size

### 3.1.1.1 Stratification design

In the stratification design, the population of interest is divided in two subgroups by prevalence in order to oversample the higher prevalence subgroup (Fig. 1F). This leads to more diseased patients and fewer non-diseased patients being recruited into the study. The oversampling is subsequently accounted for in the analyses by weighting the sensitivity and specificity of the subgroups to compute estimates for the entire population of interest [9].

The design leads to lower sample sizes overall, but every participant undergoes both index test and reference standard. This means the design can be useful when either index test or the reference standard is invasive, costly, or logistically difficult to organise.

In order to be able to oversample one subgroup within the population of interest, the stratification design requires prior knowledge on the prevalence within each stratum, and knowledge on how to distinguish the different strata. For example, if we want to evaluate the accuracy of a new test for age-related macular degeneration, prevalence of the target condition will be higher in older patients [10]. The stratification design would require knowledge of the prevalence of age-related macular degeneration in different age groups, and the sampling fraction in each age group will be determined accordingly before starting recruitment.

If screening for patient eligibility and measuring the variables that are used for stratification are themselves invasive or costly, this design may be less efficient. Additionally, it will be more efficient with greater difference in prevalence between both subgroups and a large subgroup with higher prevalence in the overall population because it results in smaller overall sample sizes for a fixed number of cases [9]. Moreover, the validity of the overall estimate relies on diagnostic accuracy across strata being similar, but it is unlikely that the data would allow formally assessing this as the stratification design leads to a low number of cases in the lowest prevalence strata. Therefore, it is important to have reasonable evidence that the characteristics of the cases detected in low and higher prevalence cases are similar. However, this evidence is often lacking and sometimes evidence shows that tests are more sensitive when the prior probability is higher.

Considering the stratification design is prospective, it is possible to undertake the index test at the point in the diagnostic pathway where it would be used in practice, increasing applicability of the results to routine care.

### 3.1.2. Designs decreasing the number of patients undergoing the index test

### 3.1.2.1 Nested case-control design

In a nested case-control study (single-gate case-control study), cases and controls are both sampled from a previously enumerated cohort ensuring representativeness (Fig. 1B) [11]. This cohort is formed by the total population of patients initially suspected of having the target condition; the diseased are all cases occurring in the suspected population and a sample of controls can be chosen randomly.

To ascertain the presence of the target condition, all cohort members need to be subjected to the reference standard. Where disease is rare, index test results are obtained from all cases, and a random sample of the controls. The nature of the index test will depend on how this is logistically done – if the test uses samples that can be safely stored at low cost, these could be obtained from all participants at the stage in the diagnostic pathway where the test would be used in clinical practice, and later selected for testing once disease status is known. For example, venous blood taken at study entry in the GRACE cohort study, was analyzed for CRP at a later stage in 100 patients with and 100 patients without pneumonia. Considering entry criteria were similar and the prevalence of pneumonia was known, diagnostic accuracy of different CRP devices could be calculated [12]. Otherwise, participants are selected to undergo the index test at a second time point once disease status is known, and the applicability of the results would be compromised if test-related health states have changed over time. Cohorts that allow further testing with a new index test are not very common, limiting the applicability of the design.

The nested case-control design is advantageous over the cohort design when obtaining the index test results is associated with high burden or cost. An increasing number of controls results in test characteristics that are more precise. A further advantage of the nested case-control design over a two-gate case-control design, in which cases and controls are sampled separately from different source populations, is the possibility to calculate positive and negative predictive values, because the sample size of the source population, i.e. the size of the cohort, with the overall disease prevalence and hence the sampling fractions are known [11].

### 3.1.2.2 Two-gate case-control design

In a diagnostic case-control study, patients with and without the disease are selected after disease status has been established, and then undergo the index test (Fig. 1D). This means that the index test will be conducted on two different source populations, hence the term two-gate case-control design [13]. The selection of these populations can greatly affect the diagnostic accuracy measures. For example, if those without disease are healthy controls, there may be fewer false positive results than when used in patients suspected of disease because alternative diagnoses may also lead to positive results on the index test, and hence specificity in healthy controls will be overestimated. Similarly, if the cases include patients with more advanced disease there may be fewer false negatives than in patients suspected of disease, and sensitivity may be overestimated [14]. Empirical evidence suggests that accuracy (expressed as a diagnostic odds ratio) may be overestimated by on average a factor of five [13]. In addition, the flow of the study is such that the index test can only be done after the disease status of patients has been established and not cannot be done at the point in the diagnostic pathway where it would be used in practice, making it less suited for target conditions that progress rapidly such as infectious diseases, or situations where test accuracy in incident cases differs from that of prevalent cases. Matching on patient covariates like patient

characteristics should be carefully considered in a case-control study as it can complicate the estimation of the added value of the test [15].

The main advantage of the case-control design is the ease of implementation and the lower cost. They have a role as an early stage study done in order to investigate whether a new test has potential and require confirmation by a different, prospective study design. Poor test accuracy in a case-control study (especially when healthy controls are used) can stop further evaluation of the test. Case-control studies using data from biobanks, like EuroBioBank and the 100,000 Genomes Project, are valuable in the evaluation of future new markers in patients with rare diseases [16,17].

A variation of the case-control design includes sampling of patients with an alternative diagnosis (instead of healthy controls) with similar symptoms as the target condition. This can result in overestimation or underestimation of the specificity measures depending on the alternative diagnosis used. For example, if the alternative diagnosis produces positive test values similar to those seen in cases, then the false positive rate is increased which results in an underestimation of specificity. Therefore, the calculated specificity cannot be applied in routine care. However, this type of evaluation provides information on the likelihood of false positive test results in specific control population(s).

### 3.1.3. Designs decreasing the number of patients undergoing the reference standard

### 3.1.3.1 Two-phase design

The objective of the two-phase design is to estimate diagnostic accuracy while not requiring that each patient in the study undergoes the reference standard (Fig. 1C). Instead, all patients receive the index test (Phase 1), but only those with a positive index test result, and a random sample of those with a negative index test result, go on to receive the reference standard (Phase 2) [9]. The sampling

fraction of those with a negative index test result is used to reweight sensitivity and specificity estimates.

The main advantage of this design in low prevalence scenarios is that it improves efficiency by prioritising positive over negative index test results, reducing the number of times the reference standard needs to be performed. This may be beneficial when the reference standard is invasive, expensive or logistically difficult to organise. An example arises in psychiatric diagnosis, when the reference standard often requires a detailed interview of the participant [18,19].

Irwig *et al*. (1994) provide estimates of the resulting savings in sample size for different sensitivity and specificity combinations and conclude that greater savings accrue for lower values of sensitivity [20]. Therefore, when the expected sensitivity is high, the total number of patients recruited is often increased compared to cohort design [9]. Consequently, the design is more suited to situations in which the index test is inexpensive or routinely used. In all designs, bias may occur if there is differential dropout, but this design is more exposed to this particular type of bias because the reference standard is often invasive and there could be a time period between the two phases. The index test can be evaluated at a point in the diagnostic pathway where it would be used in practice.

Baker *et al.* (1998) discuss a similar design that they term a "partial testing design", in which a sampling fraction for Phase 2 testing (reference standard) is also employed among individuals who receive an initial positive result [21]. Moreover, a third phase could be used in which patients who did not undergo the reference standard are followed up for a certain period of time [21].

### 3.1.3.2 Comparing two tests without verification of double negatives

A design used for evaluating tests when the accuracy of two alternative index tests needs to be compared involves both index tests being used in all recruited participants, but only those found to

be positive on at least one of the index tests receiving the reference standard (Fig. 1E) [22-24]. This design can be very efficient in low prevalence situations, particularly for index tests with high specificity, as none of the many individuals who are negative on both tests undergo the reference standard investigation. This may be particularly desirable when the reference standard is invasive or expensive. Whilst it is not possible to obtain estimates of the actual sensitivity and specificity of either test from this design, valid estimates of the relative sensitivity and relative false positive (1-specificity) fractions can be obtained, together with valid tests of their statistical significance [23]. If one test shows higher true positive and lower false positive rates clearly, dominance can be concluded; should one test show both higher true positive and higher false positive rates the preferred test depends on the ratio of extra true positives to extra false negatives which can also be computed [23].  If required, estimates of sensitivity and specificity for both tests could be estimated indirectly if values for one test are known from existing studies, or additionally verifying a random sample of participants with both test negative as in a Two-Phase Design and using a weighted analysis.

A requirement for use of this study design is that it is acceptable and ethical to use both index tests at the same time in each individual. This may not be possible if index tests are burdensome or if the quantity of specimen available for analysis is inadequate. The interpretation of each index test should also be undertaken independently.

### 3.1.4. Design for multiple tests and multiple conditions

### 3.1.4.1 Comprehensive diagnostic study design

All study designs discussed so far have in common that they evaluate the accuracy of index tests for one target condition only. Primary care physicians, however, are confronted with a wide range of conditions. The comprehensive diagnostic study provides estimates of test accuracy of multiple

index tests and for more than one target condition, including more and less prevalent conditions (Fig. 1G) [25].

Patients are recruited on the basis of a particular symptom or finding. For each patient, further symptoms, physical findings and the results of investigations recorded. Some tests are mandatory, others are left at the discretion of the clinician. Depending on the disease in question, patients are followed for a defined period, after which a reference panel reviews clinical data to determine each patient's status regarding the target conditions of interest [26].

As a result, the efficiency of a comprehensive diagnostic study is in providing estimates of the prevalence [27] and accuracy of selected diagnostic tests for several target conditions in a single study. Moreover, it allows the derivation and validation of complex prediction rules or strategies for the presenting problem, which may include complex algorithms for computerized decision support systems.

While a comprehensive diagnostic study closely reflects real life, especially for primary care clinicians, the amount of data required may pose logistical, ethical and financial challenges. Moreover, there are no efficiencies in this design for the accuracy of a single test for a low prevalence condition. However, it allows information to be gleaned about low prevalence conditions alongside others that have higher prevalence, which potentially makes it a more efficient design than doing separate independent studies for each disease.

### 4. Practical recommendations for design choice in low prevalence situations

Table 1 provides a general guide of the three most suitable designs for different low prevalence situations, taking into account their respective advantages and limitations. In addition, it is important to specify the goal for which a test is used and whether it is more important to have a high sensitivity or a particularly high specificity, and estimate these with sufficient precision. For

13

example, a triage test requires a high sensitivity and an invasive or dangerous follow-up or treatment requires a high specificity. If sensitivity is considered more important than specificity, it is a challenge to estimate this with sufficient precision in low prevalence settings. However, estimating specificity with sufficient precision is less of a problem in relation to low prevalence, because there are more non-diseased patients than diseased.

When the index test is costly or invasive, three options are available: the nested case-control design reduces the number of index tests by testing a random sample of patients with a negative reference standard and all patients with a positive reference standard, resulting in a low risk of bias. We consider the stratification design a good alternative when it is difficult to recruit a large population in general, or when the index test cannot be performed after the selection of the cases, e.g. no stored data/samples available or the target condition if progressing rapidly. Finally, a two-gate case-control design is the last option but is prone to bias.

To compare the diagnostic properties of more than one index test, one could opt for a study in which patients who have a negative test result for both tests are not verified. The design will allow ranking of the two index tests based on the number of false positives for each true positives detected by one test compared to the other. Two other designs could be considered: stratification design and two-phase design. The stratification design results in higher savings than the two-phase design [9].

When the reference standard is costly or invasive, two designs would apply: the two-phase design and the design comparing two tests without verification of double negatives. Although the latter results in a higher reduction in the number of patients having to undergo the reference standard, this design only allows calculating the relative true positive and negative rates. Therefore, the two-phase design is the first choice as it provides unbiased estimates of test characteristics. The stratification design reduces the overall sample size and therefore this design could be considered as a third option in this situation.

### 5. Using routine care data

The use of routine data has become increasingly popular in all types of research including diagnostic accuracy studies. Some of the most known routine datasets include the Clinical Practice Research Database (CPRD) [28], The Health Improvement Network (THIN) [29] and Interdisciplinary Processing of Clinical Information (IPCI) [30] which are all based on routine medical records, mostly from primary care.

The perceived advantages of using routine datasets is that they contain adequate numbers of patients to allow the investigation of (very) rare diseases without prolonged phases of recruitment, they provide a wealth of information including demographic information, symptoms, diagnoses and laboratory investigations, and they allow conducting studies with long term follow-up [31-33] .

Despite these advantages, routine datasets also have weaknesses, one of the most common problems being missing data [34]. Due to the fact that the data are not collected with research purposes in mind there are varying degrees of completeness across patients and across time, and data is unlikely to be missing at random [35]. A second issue is that the suspicion of disease is often not recorded and therefore the suspected population cannot be created. A third issue is that it is often unclear why individuals received particular medical investigations and it is rarely recorded for which target condition a test is used. Local availability of diagnostic testing or medical tradition may have an impact on diagnostic labelling. A fourth issue is that routine datasets also rely on routinely made diagnoses, which can introduce bias because it assumes that every patient eventually receives the correct diagnostic label, which is not necessarily true. There also may be large variation in diagnostic labelling of target conditions for which there is no clear definition. Finally, routine care data do not allow the evaluation of innovative or experimental tests that are not part of routine clinical practice. For evaluating medical tests these issues could lead to verification bias, information

bias, and applicability concerns [34]. Assumptions and clinical judgement will be required to judge the impact of these issues and select appropriate methods to deal with them.

## 6. Discussion

We provide an overview of existing designs and methods, each with their advantages and limitations, which can help researchers in designing a diagnostic accuracy study in low prevalence situations. Study designs can be distinguished by their ability to decrease the number of patients undergoing the index test or reference standard respectively, and their risks of bias. Combinations of designs could be considered as well. For example, a two-phase design with stratification in the first phase could offer more savings compared to each design separately [9]. Another example is that a nested case-control design could be performed using data from the comprehensive diagnostic study design. Moreover, adaptive designs in which the prevalence of the disease is monitored during the study could be efficient as the prevalence of the disease can vary a lot and the sampling variation is large in low prevalence studies [36,37].

Nonetheless, situations exist in which none of these designs or methods may be possible. For example, bacterial meningitis is now estimated to occur in 0.7–0.9 per 100 000 people per year in Western countries [38]. Considering bacterial meningitis is a rapidly evolving illness, (nested) case-control designs would prove problematic because any symptom or biomarker is likely to have changed after the diagnosis has been established and stored samples are unlikely to be available for an acute, mostly paediatric population. The reference standard is lumbar puncture, which is invasive and preferably avoided in patients at low risk of meningitis. This leaves the options of the two-phase design, two index tests without verification of double negatives, and the stratification design. In order for the two-phase design to result in fairly precise estimates of specificity, the index test would have to be sufficiently accurate, in particular with few false positives because otherwise the sample size will still be quite large. Similarly, for the design in which patients are not verified when testing

negative on two index tests: considering bacterial meningitis is potentially lethal, the accuracy of both the index tests needs to be sufficient in order to risk not verifying patients who test negative on both. Finally, for the stratification design, finding variables with which the population can be stratified safely (e.g. fever and head/neck ache) could be challenging as there is little evidence on their distribution within the population precisely because of the very low prevalence in contemporary clinical practice.

A limitation is that we could have missed studies, because it is a disease independent systematic review. However, by performing an extensive search in four libraries, backward citation tracking and consultation of experts we believe it is highly likely that all relevant studies were included. We did not include designs which provide biased estimates of test accuracy, e.g. the enriched design in which only positive index tests receive a reference standard. In addition, the evaluation of the diagnostic accuracy of a test is only one step in the evaluation of diagnostic tests [39]. It is desirable to evaluate whether a test actually improves the care of patients. To provide suggestions for diagnostic impact studies in low prevalence situations was beyond the aim of this study. Moreover, the included papers do not give details of the receiver operating characteristics (ROC) curve in relation to low prevalence situations, while the ROC-curve is particularly vulnerable to low events rates, as ROC estimation requires substantial sample sizes [40].

We recommend researchers explore their options before the start of any diagnostic accuracy study, by listing all the prerequisite criteria including expected prevalence in their setting, any evidence on subgroups within the population, the index test with its associated harms and costs, the reference standard again with harms and costs, and the target condition including its rapidity of disease progression. In addition, the goal of the test will influence which accuracy parameters will need to be estimated with the most precision [41]. This will guide researchers in identifying the options available and select the best option based on their respective risks of bias.

**Acknowledgement**

We are grateful to Gail Hayward and Ellie Morgan-Jones of the NIHR Community Healthcare

MedTech and In Vitro Diagnostic Co-operative (MIC) for facilitating the one-day meeting.

**Table 1.** Clinical examples of different designs for diagnostic accuracy studies in low prevalence situation

| Design | Population | Target condition | Index test | Reference standard |
|---|---|---|---|---|
| Stratification design (Obuchowski 2002) [9] | Patients with and without coronary artery disease (CAD) | Myocardial infarctions | New test for silent myocardial infarctions (MI) | Magnetic Resonance Imaging |
| Two-phase design (Duvekot 2015) [19] | Children referred to mental health centers | Autism Spectrum Disorder | Parent and teacher-reported Social Responsiveness Scale (SRS) | Developmental, Dimensional, and Diagnostic interview (3Di) and Autism Diagnostic Observation Schedule (ADOS) |
| Two-gate case-control design (Ukoumunne 2017) [42] | Cases: hearing impaired children recruited from audiology services Controls: children with no previous identified impairment recruited from schools | Hearing impairment | Pure tone screen and HearCheck Screener | Pure tone audiometry |
| Nested case-control design (Minnaard 2015) [43] | Adult patients presenting with acute cough (the Genomics to combat Resistance against Antibiotics in Community-acquired LRTI in Europe [GRACE] Network) | Pneumonia | Five point-of-care test devices for estimating C-reactive protein (CRP) and the laboratory analyser | Chest radiographs |
| Comparing two tests without verification of double negatives design (Armitage 1985) [44] | Colorectal cancer screening population | Colorectal cancer | Two faecal occult blood tests (chemical and immunological test) | Sigmoidoscopy |
| Comprehensive diagnostic study design (Bosner 2009 and Donner-banzhoff 2014) [25,45] | Patients presenting with chest pain in primary care | Multiple outcome categories, e.g. acute coronary syndrome, severe respiratory disorders, psychogenic causes | Symptoms and findings | Interdisciplinary reference panel reviewed clinical data of each patient |

**Table 2.** General guide for designs in different low prevalence situations.

| | Stratification design | Nested case-control design | Case-control design | Two-phase design | Comparing two tests without verification of double negatives | Comprehensive diagnostic study design |
|---|---|---|---|---|---|---|
| **Low prevalence situation:** | | | | | | |
| *Population* | | | | | | |
| Different strata in patient population | Only option | | | | | |
| Predefined cohort | | Only option | | | | |
| *Index test* | | | | | | |
| Costly or invasive index test | Second option | First option | Third option | | | |
| Two index tests | Second option | | | Third option | First option | |
| Multiple index tests | | | | | | Only option |
| *Reference standard* | | | | | | |
| Costly or invasive reference standard | Third option | | | First option | Second option | |
| *Target condition* | | | | | | |
| Extremely low prevalence (<0.1%) | | | Only option* | | | |
| Multiple target conditions | | | | | | Only option |
| **Main issues QUADAS-2** | Higher risk of bias if there is more difference between prevalence strata | Higher risk of bias if the selection of index test is not random and if the index test is done outside the care pathway | Higher risk of bias if cases or controls do not represent the same population and if index test is done outside the care pathway | Higher risk of bias if the selection of reference standard is not random | Higher risk of bias if both index tests are not blinded from each other | Higher risk of bias if there is no reference panel to determine the diagnosis |

Note: If there were more than one design applicable, the first three options were ranked on suitability based on sample size and risk of bias. Other designs might be possible as well in specific situations.

*Another option is to conduct a cohort study using routine healthcare data containing millions of patients.

**Cohort of consecutive patients suspected of disease**

Index test

Reference standard

Disease | No Disease

1A. Cohort design

## Decreasing number of patients undergoing index test

**Cohort of consecutive patients suspected of disease**

Reference standard

Disease | No Disease

All | Random sample

Index test

1B. Nested case-control design

## Decreasing number of patients undergoing reference standard

**Cohort of consecutive patients suspected of disease**

Index test positive | Index test negative

All | Random sample

Reference standard

Disease | No Disease

1C. Two-phase design

Cases

Index test

Controls

Index test

1D. Two-gate case-control design

**Cohort of consecutive patients suspected of disease**

One or both Index test positive | Both Index tests negative

Reference standard

Disease | No Disease

1E. Comparing two tests

## Decreasing total number of patients

Low risk group | High risk group

Oversampling high risk group

Low risk group | High risk group

Index test

Reference standard

Disease | No Disease

1F. Stratification design

## Multiple tests for multiple conditions

**Cohort of consecutive patients suspected of disease**

Multiple index tests

Reference panel reviews clinical data

Several diseases

1G. Comprehensive diagnostic study design

**Figure 1.** Study designs for diagnostic accuracy studies.



**Figure 2.** Sample size for the classical design of diagnostic test accuracy studies with different disease prevalences.

Sample size calculation is based on the following equations [5]:

**Number with disease needed:**

$$TP + FN = Z_{\alpha/2}^2 \frac{SN(1-SN)}{W^2}$$

**Sample size needed for sensitivity:**

$$N_{sens} = \frac{TP + FN}{P}$$

**Number without disease needed:**

$$FP + TN = Z_{\alpha/2}^2 \frac{SP(1-SP)}{W^2}$$

**Sample size needed for specificity:**

$$N_{spec} = \frac{FP + TN}{(1-P)}$$

W = half width of the 95% CI
$Z_{\alpha/2}$= for 2-tailed 95% CIs, $\alpha$ = 0.05 and $Z_{\alpha/2}$ = 1.96
P = prevalence of disease in the target population
SN = expected sensitivity of the index test

SP = expected specificity of the index test

**Appendix 1.** Search strategies

**MEDLINE search strategy**

1.  "diagnostic techniques and procedures"/ or diagnostic tests, routine/
2.  Research Design/
3.  Algorithms/
4.  2 or 3
5.  1 and 4
6.  *Diagnostic Tests, Routine/
7.  Diagnostic Tests, Routine/mt [Methods]
8.  (diagnos* adj2 (stud* or test* or accuracy) adj5 (design* or model)).ti,ab.
9.  (diagnos* and (stud* or test* or accuracy) and (design* or model)).ti.
10. diagnos*.ti,ab. and (Research Design/ or Algorithms/)
11. "Sensitivity and Specificity"/ and Research Design/
12. 6 or 7 or 8 or 9 or 10 or 11
13. (low* adj5 (incidence or prevalence) adj5 (disease* or illness* or disorder*)).ti,ab.
14. (low* adj5 (incidence or prevalence) adj5 diagnos*).ti,ab.
15. ((rare or uncommon or serious or severe) adj5 (disease* or illness* or disorder*)).ti,ab.
16. ((incidence or prevalence) and (disease* or illness* or disorder*)).ti.
17. Cross-Sectional Studies/
18. Case-Control Studies/
19. 13 or 14 or 15 or 16 or 17 or 18
20. 12 and 19
21. (low* and (incidence or prevalence) and diagnos*).ti.
22. 5 or 20 or 21

**EMBASE search strategy**

1. diagnostic test/ or diagnostic procedure/
2. *methodology/ or *experimental design/
3. *Algorithm/
4. 2 or 3
5. 1 and 4
6. *diagnostic test/ or *diagnostic procedure/
7. (diagnos* adj2 (stud* or test* or accuracy) adj5 (design* or model)).ti,ab.
8. (diagnos* and (stud* or test* or accuracy) and (design* or model)).ti.
9. diagnos*.ti,ab. and (*methodology/ or *experimental design/ or *Algorithm/)
10. "Sensitivity and Specificity"/ and (*methodology/ or *experimental design/)
11. (diagnostic accuracy/ or predictive validity/ or predictive value/) and (*methodology/ or *experimental design/)
12. (diagnostic accuracy/ or predictive validity/ or predictive value/) and Algorithm/
13. 6 or 7 or 8 or 9 or 10 or 11 or 12
14. (low* adj5 (incidence or prevalence) adj5 (disease* or illness* or disorder*)).ti,ab.
15. (low* adj5 (incidence or prevalence) adj5 diagnos*).ti,ab.
16. ((rare or uncommon or serious or severe) adj5 (disease* or illness* or disorder*)).ti,ab.
17. ((incidence or prevalence) and (disease* or illness* or disorder*)).ti.
18. cross-sectional study/
19. case control study/
20. 14 or 15 or 16 or 17 or 18 or 19
21. 13 and 20
22. (low* and (incidence or prevalence) and diagnos*).ti.
23. 5 or 21 or 22

**Web of Science search strategy**

#1    TOPIC: ((diagnos* NEAR/2 (stud* or test* or accuracy) NEAR/5 (design* or model))) OR TITLE: ((diagnos* and (stud* or test* or accuracy) and (design* or model)))

#2    TOPIC: ((low* NEAR/5 (incidence or prevalence) NEAR/5 (disease* or illness* or disorder*))) OR TOPIC: ((low* NEAR/5 (incidence or prevalence) NEAR/5 diagnos*)) OR TOPIC: (((rare or uncommon or serious or severe) NEAR/5 (disease* or illness* or disorder*))) OR TITLE: (((incidence or prevalence) and (disease* or illness* or disorder*)))

#3    #2 AND #1

#4    TITLE: ((low* and (incidence or prevalence) and diagnos*))

#5    #4 OR #3

**Cochrane Library search strategy**

#1      MeSH descriptor: [Diagnostic Tests, Routine] explode all trees

#2      MeSH descriptor: [Diagnostic Techniques and Procedures] this term only

#3      MeSH descriptor: [Sensitivity and Specificity] this term only

#4      #1 or #2 or #3

#5      MeSH descriptor: [Research Design] this term only

#6      MeSH descriptor: [Algorithms] this term only

#7      #5 or #6

#8      #4 and #7

#9      MeSH descriptor: [Diagnostic Tests, Routine] explode all trees

#10     (diagnos* near/2 (stud* or test* or accuracy) near (design* or model)):ti,ab,kw  (Word variations have been searched)

#11     (diagnos* and (stud* or test* or accuracy) and (design* or model)):ti  (Word variations have been searched)

#12     #9 or #10 or #11

#13     (low* near (incidence or prevalence) near (disease* or illness* or disorder*)):ti,ab,kw  (Word variations have been searched)

#14     (low* near (incidence or prevalence) near diagnos*):ti,ab,kw  (Word variations have been searched)

#15     ((rare or uncommon or serious or severe) near (disease* or illness* or disorder*)):ti,ab,kw (Word variations have been searched)

#16     ((incidence or prevalence) and (disease* or illness* or disorder*)):ti  (Word variations have been searched)

#17     cross-sectional stud* or "case-control stud*":ti,ab,kw  (Word variations have been searched)

#18     #13 or #14 or #15 or #16 or #17

#19     #12 and #18

#20     (low* and (incidence or prevalence) and diagnos*):ti  (Word variations have been searched)

#21     #8 or #19 or #20

```
┌─────────────────────────────────────────────────────┐
│ Records identified through database searching        │
│                   (n=5170)                           │
│                                                      │
│ Cochrane Database of Systematic reviews (n=20)       │
│ Cochrane Methodology Register (n=6)                  │
│ Database of Abstracts of Reviews of Effects (n=81)   │
│ Embase (n=1752)                                      │
│ MEDLINE (n=3051)                                     │
│ Web of Science (n=260)                               │
└─────────────────────────────────────────────────────┘
                          │
                          ▼
        ┌─────────────────────────────────────┐
        │ Records after duplicates removed     │
        │             (n=4185)                 │
        └─────────────────────────────────────┘
                          │
                          ▼
        ┌──────────────────────┐       ┌──────────────────────┐
        │ Records screened      │──────▶│ Records excluded      │
        │     (n=4185)          │       │     (n=4050)          │
        └──────────────────────┘       └──────────────────────┘
                          │
                          ▼
        ┌──────────────────────┐       ┌───────────────────────────────────────────┐
        │ Full-text articles    │──────▶│ Full-text articles excluded (n=125):       │
        │ assessed for          │       │   Low prevalence issues not discussed (n=95)│
        │ eligibility           │       │   Diagnostic studies not discussed (n=11)   │
        │     (n=135)           │       │   Low prevalence issues discussed but no    │
        └──────────────────────┘       │   methodological solutions (n=8)            │
                          ▲            │   Methods to estimate prevalence (n=7)       │
┌──────────────────────────┐          │   Methods to adjust for different prevalence │
│ Additional articles       │─────▶    │   or spectrum (n=3)                         │
│ identifitied by experts   │          │   Recommendations for screening tests (n=1) │
│ (n=3)                     │          └───────────────────────────────────────────┘
└──────────────────────────┘
                          ▲
┌──────────────────────────┐
│ Additional articles       │─────▶
│ identified by backward    │
│ citation (n=3)            │
└──────────────────────────┘
                          │
                          ▼
        ┌──────────────────────┐
        │ Studies included      │
        │     (n=16)            │
        └──────────────────────┘
```

**Appendix 2.** Flow diagram summarizing study selection.

**Appendix 3.** Characteristics of included studies.

| Study | Design | Analytic considerations | Using routine healthcare data |
|---|---|---|---|
| Baker et al 1998 [21] | Two-phase design | | |
| Berry et al 2002 [22] | Comparing two index tests without verification of double negatives | | |
| Biesheuvel et al 2008 [11] | Nested case-control design | | |
| Bjork et al 2009 [46] | | Population weighting | |
| Brinton et al 2015 [37] | | Sample size calculation | |
| Buntix et al 2011 [6] | | | Routine healthcare data and large prospective cohort studies |
| Chock et al 1997 [23] | Comparing two index tests without verification of double negatives | | |
| Donner-Banzhoff et al 2014 [25] | Comprehensive diagnostic study design | | |
| Irwig et al 1994 [20] | Two-phase design | | |
| Obuchowski et al 2002 [9] | -Stratification design -Two-phase design | | |
| Oostenbrink et al 2003 [34] | | | Routine healthcare data |
| Pavlou et al 2015 [47] | | Logistic regression in small data sets | |
| Rutjes et al 2005 [13] | Various case control designs | | |
| Schatzkin et al 1987 [24] | Comparing two index tests without verification of double negatives | | |
| Van Smeden et al 2016 [48] | | Logistic regression in small data sets | |
| Yi et al 2004 [36] | | Sample size calculation | |

**Appendix 4.** Analytical considerations

**Sample size calculations**

Sample size calculations in low prevalence settings focus on the estimates of sensitivity; sample sizes for estimating specificity are typically adequate to obtain informative estimates. Methods for estimation of sample size for single-test studies are most commonly based on achieving pre-stated levels of precision for estimates of sensitivity, and on consideration of the statistical power to detect differences in sensitivity in two-test studies [5,49]. However, where a single test is to be compared with a minimum sensitivity value, the statistical power approach can also be used for single-test studies. Standard methods for estimating confidence interval width for proportions as used in the classic design apply directly to case-control and nested case-control design, but require adaptations to account for sampling fractions when applied to stratified and two-stage designs [9]. R files which do sample size calculations for each design can be requested from the first author.

When comparing the accuracy of two tests in a situation where both tests are undertaken in all participants, provides us with the opportunity to include the correlation between false negative results for the two tests when estimating the required sample size for sensitivity [9]. Assuming independence of tests errors is a conservative option over assuming the likely positive correlation of test errors. Accounting for sampling designs when determining sample size in paired designs is best undertaken by simulating the study across fixed sample sizes and estimating power from the proportion of simulations in which the statistical significance test of differences in sensitivity is rejected at the chosen significance level. Simulation approaches also allow assessment of power for other statistical parameters, such as predictive values.

It is important to consider the impact of stochastic error in the number of cases observed at a known prevalence on statistical power – this can be directly accounted for should simulation be used to determine

sample size, but can also be adjusted for using methods of Flahault et al [50]. Given the possibility of

misspecification of the prevalence it may be wise to check on the observed prevalence at interim points to

assess whether sample size modification is required.

**Computation of confidence intervals**

Sensitivity and specificity are proportions, and methods used for computing confidence intervals for

proportions can be utilised. However, as the number of participants used for computing estimates of

sensitivity is often low, the validity of normal approximation based methods is questionable in many

circumstances, particularly for high values of sensitivity. Exact binomial approaches are likely to be preferred,

which will yield asymmetric intervals [51].

**Weighted analyses**

Failure to account for the sampling structure used in stratified, two-phase and case-control designs in analysis

will introduce bias in estimates of sensitivity and specificity (in stratified and two-phase designs), and

predictive values (in stratified, case-control and nested case-control designs) [9,11]. Weighted analyses which

account for the sampling probability of each participant's inclusion produce unbiased estimates and

confidence intervals, although all methods rely on the use of normal approximations (the validity of

reweighting methods for estimates of sensitivity and specificity close to 100% requires investigation). Whilst

sampling probabilities will be known for stratified, two-phase and nested case-control designs, they may be

unknown for non-nested case-control studies.

**Binary logistic regression**

When developing a clinical prediction rule, the candidate predictors such as symptoms or blood tests should

be carefully reviewed based on previous research and knowledge to select those most promising for further

evaluation. Moreover, a low number of events compared with the number of predictors could provide

imprecise and extreme predictions. This is also known as overfitting. Internal bootstrap based validity can be

used to estimate the degree of overfitting and estimate adjustments required for over optimism. When it occurs alternative methods such as penalised regression can be used to provide more accurate predictions [47,48]. This method shrinks the regression coefficient by using constraints which results in less extreme predictions. Several penalised methods can be used, e.g. Firth, Lasso, Ridge. Other methods to reduce the number of predictors, such as backward stepwise selection give biased regression coefficients and should be avoided. Penalised regression is only applicable in the development phase of a clinical prediction rule and not in the validation phase. Assistance of a statistician is recommended as there are multiple approaches.

**Population weighting**

The performance of diagnostic tests can vary in different patient populations. A new diagnostic test for cancer might be highly sensitive for people in the latter stages of disease but less sensitive when the disease is in the early stages. Another test may always be negative in the "wellest of the well" but prone to false positives when used on patients with diseases within the same anatomical location [52]. Bjork *et al.* proposed a method for assessing the variability of diagnostic test accuracy in different types of populations (e.g. low prevalence settings) using only stratum specific diagnostic accuracy measures from a single study [46]. Variation can be assessed by calculating average performance weighted by population case-mix. This is essentially a "paper exercise " but one which could be useful to quickly rule out the use of diagnostic tests in low prevalence studies or to inform sample size calculations. Appendix Table 1 illustrates the population weighting approach in a hypothetical example of estimating overall sensitivity of natriuretic peptides to detect heart failure in a low prevalence setting.

**Appendix Table 1.** Example of population weighting approach

| New York Heart Association (NYHA) stage | I | II | III | IV |
|---|---|---|---|---|
| Stratum specific sensitivity to detect HF using threshold of NP = 100 pg/ml | 67% | 78% | 84% | 100% |
| Proportion of patients in primary care population | 30% | 57% | 12% | 1% |

| Estimated sensitivity using primary care population weighting approach IV | (67*0.3 + 78*0.57 + 84*0.12 + 100*0.01) = 75.6% |
|---|---|

## References

[1] Hamilton W, Peters TJ, Round A, Sharp D. What are the clinical features of lung cancer before the diagnosis is made? A population based case-control study. Thorax 2005;60:1059-65.

[2] Van den Bruel A, Aertgeerts B, Bruyninckx R, Aerts M, Buntinx F. Signs and symptoms for diagnosis of serious infections in children: a prospective study in primary care. Br J Gen Pract 2007;57:538-46.

[3] Holtman GA, Lisman-van Leeuwen Y, Kollen BJ, Norbruis OF, Escher JC, Kindermann A, et al. Diagnostic Accuracy of Fecal Calprotectin for Pediatric Inflammatory Bowel Disease in Primary Care: A Prospective Cohort Study. Ann Fam Med 2016;14:437-45.

[4] Holtman GA, Lisman-van Leeuwen Y, Kollen BJ, Escher JC, Kindermann A, Rheenen PF, et al. Challenges in diagnostic accuracy studies in primary care: the fecal calprotectin example. BMC Fam Pract 2013;14:179,2296-14-179.

[5] Buderer NM. Statistical methodology: I. Incorporating the prevalence of disease into the sample size calculation for sensitivity and specificity. Acad Emerg Med 1996;3:895-900.

[6] Buntinx F, Mant D, Van den Bruel A, Donner-Banzhof N, Dinant GJ. Dealing with low-incidence serious diseases in general practice. Br J Gen Pract 2011;61:43-6.

[7] Wade R, Corbett M, Eastwood A. Quality assessment of comparative diagnostic accuracy studies: our experience using a modified version of the QUADAS-2 tool 2013;4:280-6.

[8] Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies. Ann Intern Med 2011;155:529-36.

[9] Obuchowski NA, Zhou XH. Prospective studies of diagnostic test accuracy when disease prevalence is low. Biostatistics 2002;3:477-92.

[10] Colijn JM, Buitendijk GH, Prokofyeva E, Alves D, Cachulo ML, Khawaja AP, et al. Prevalence of age-related macular degeneration in Europe: the past and the future. Ophthalmology 2017;124:1753-63.

[11] Biesheuvel CJ, Vergouwe Y, Oudega R, Hoes AW, Grobbee DE, Moons KG. Advantages of the nested case-control design in diagnostic research. BMC Med Res Methodol 2008;8:48,2288-8-48.

[12] Minnaard MC, Van De Pol, Alma C, De Groot JA, De Wit NJ, Hopstaken RM, Van Delft S, et al. The added diagnostic value of five different C-reactive protein point-of-care test devices in detecting pneumonia in primary care: a nested case-control study. Scand J Clin Lab Invest 2015;75:291-5.

[13] Rutjes AW, Reitsma JB, Vandenbroucke JP, Glas AS, Bossuyt PM. Case-control and two-gate designs in diagnostic accuracy studies. Clin Chem 2005;51:1335-41.

[14] Kohn MA, Carpenter CR, Newman TB. Understanding the direction of bias in studies of diagnostic test accuracy. Acad Emerg Med 2013;20:1194-206.

[15] Janes H, Pepe MS. Matching in studies of classification accuracy: implications for analysis, efficiency, and assessment of incremental value. Biometrics 2008;64:1-9.

[16] Mora M, Angelini C, Bignami F, Bodin A, Crimi M, Di Donato J, et al. The EuroBioBank Network: 10 years of hands-on experience of collaborative, transnational biobanking for rare diseases 2015;23:1116.

[17] Turnbull C, Scott RH, Thomas E, Jones L, Murugaesu N, Pretty FB, et al. The 100000 genomes project: Bringing whole genome sequencing to the NHS 2018;361.

[18] Dunn G, Pickles A, Tansella M, Vázquez-Barquero JL. Two-phase epidemiological surveys in psychiatric research 1999;174:95-100.

[19] Duvekot J, van der Ende J, Verhulst FC, Greaves-Lord K. The screening accuracy of the parent and teacher-reported Social Responsiveness Scale (SRS): Comparison with the 3Di and ADOS. J Autism Dev Disord 2015;45:1658-72.

[20] Irwig L, Glasziou PP, Berry G, Chock C, Mock P, Simpson JM. Efficient study designs to assess the accuracy of screening tests. Am J Epidemiol 1994;140:759-69.

[21] Baker SG, Connor RJ, Kessler LG. The partial testing design: a less costly way to test equivalence for sensitivity and specificity. Stat Med 1998;17:2219-32.

[22] Berry G, Smith CL, Macaskill P, Irwig L. Analytic methods for comparing two dichotomous screening or diagnostic tests applied to two populations of differing disease prevalence when individuals negative on both tests are unverified. Stat Med 2002;21:853-62.

[23] Chock C, Irwig L, Berry G, Glasziou P. Comparing dichotomous screening tests when individuals negative on both tests are not verified. J Clin Epidemiol 1997;50:1211-7.

[24] Schatzkin A, Connor RJ, Taylor PR, Bunnag B. Comparing new and old screening tests when a reference procedure cannot be performed on all screenees: example of automated cytometry for early detection of cervical cancer. Am J Epidemiol 1987;125:672-8.

[25] Donner-Banzhoff N, Haasenritter J, Hullermeier E, Viniol A, Bosner S, Becker A. The comprehensive diagnostic study is suggested as a design to model the diagnostic process. J Clin Epidemiol 2014;67:124-32.

[26] Knottnerus JA, Muris JW. Assessment of the accuracy of diagnostic tests: the cross-sectional study. J Clin Epidemiol 2003;56:1118-28.

[27] Donner-Banzhoff N, Kunz R, Rosser W. Studies of symptoms in primary care. Fam Pract 2001;18:33-8.

[28] Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol 2015;44:827-36.

[29] Anonymous . In Practice Systems Ltd. The Health Improvement Network (THIN). 2016; http://www.inps.co.uk/vision/health-improvement-network-thin. Accessed 5 July 2016.

[30] Anonymous . Mosseveld B. Interdisciplinary Processing of Clinical Information. 2015. Available from: http://www.ipci.nl/Framework/Framework.php (20th of February 2018)
.

[31] Miller A, Nightingale AL, Sammon CJ, Mahtani KR, Holt TA, McHugh NJ, et al. Estimating the diagnostic accuracy of rheumatoid factor in UK primary care: a study using the Clinical Practice Research Datalink. Rheumatology 2015;54:1882-9.

[32] Hippisley-Cox J, Coupland C. Identifying patients with suspected colorectal cancer in primary care: derivation and validation of an algorithm. Br J Gen Pract 2012;62:e29-37.

[33] Rees F, Doherty M, Lanyon P, Davenport G, Riley RD, Zhang W, et al. Early clinical features in systemic lupus erythematosus: Can they be used to achieve earlier diagnosis? A risk prediction model 2017;69:833-41.

[34] Oostenbrink R, Moons KG, Bleeker SE, Moll HA, Grobbee DE. Diagnostic research on routine care data: prospects and problems. J Clin Epidemiol 2003;56:501-6.

[35] Sammon CJ, Miller A, Mahtani KR, Holt TA, McHugh NJ, Luqmani RA, et al. Missing laboratory test data in electronic general practice records: analysis of rheumatoid factor recording in the clinical practice research datalink. Pharmacoepidemiol Drug Saf 2015;24:504-9.

[36] Yi Q, Panzarella T, Corey P. Incorporating the sampling variation of the disease prevalence when calculating the sample size in a study to determine the diagnostic accuracy of a test. Control Clin Trials 2004;25:417-27.

[37] Brinton JT, Ringham BM, Glueck DH. An internal pilot design for prospective cancer screening trials with unknown disease prevalence 2015;16:458.

[38] Brouwer MC, van de Beek D. Epidemiology of community-acquired bacterial meningitis. Curr Opin Infect Dis 2018;31:78-84.

[39] Horvath AR, Lord SJ, StJohn A, Sandberg S, Cobbaert CM, Lorenz S, et al. From biomarkers to medical tests: the changing landscape of test evaluation 2014;427:49-57.

[40] Hanczar B, Hua J, Sima C, Weinstein J, Bittner M, Dougherty ER. Small-sample precision of ROC-related estimates. Bioinformatics 2010;26:822-30.

[41] Bossuyt PM, Irwig L, Craig J, Glasziou P. Comparative accuracy: assessing new tests against existing diagnostic pathways. BMJ 2006;332:1089-92.

[42] Ukoumunne OC, Hyde C, Ozolins M, Zhelev Z, Errington S, Taylor RS, et al. A directly comparative two-gate case-control diagnostic accuracy study of the pure tone screen and HearCheck screener tests for identifying hearing impairment in school children. BMJ Open 2017;7:e017258,2017-017258.

[43] Minnaard MC, Van De Pol, Alma C, De Groot JA, De Wit NJ, Hopstaken RM, Van Delft S, et al. The added diagnostic value of five different C-reactive protein point-of-care test devices in detecting pneumonia in primary care: a nested case-control study. Scand J Clin Lab Invest 2015;75:291-5.

[44] Armitage N, Hardcastle J, Amar S, Balfour T, Haynes J, James P. A comparison of an immunological faecal occult blood test Fecatwin sensitive/FECA EIA with Haemoccult in population screening for colorectal cancer. Br J Cancer 1985;51:799.

[45] Bösner S, Becker A, Haasenritter J, Abu Hani M, Keller H, Sönnichsen AC, et al. Chest pain in primary care: epidemiology and pre-work-up probabilities 2009;15:141-6.

[46] Bjork J, Grubb A, Nyman U. Variability in diagnostic accuracy can be estimated using simple population weighting. J Clin Epidemiol 2009;62:54-7.

[47] Pavlou M, Ambler G, Seaman SR, Guttmann O, Elliott P, King M, et al. How to develop a more accurate risk prediction model when there are few events. BMJ 2015;351:h3868.

[48] van Smeden M, de Groot JA, Moons KG, Collins GS, Altman DG, Eijkemans MJ, et al. No rationale for 1 variable per 10 events criterion for binary logistic regression analysis 2016;16:163.

[49] Hayen A, Macaskill P, Irwig L, Bossuyt P. Appropriate statistical methods are required to assess diagnostic tests for replacement, add-on, and triage. J Clin Epidemiol 2010;63:883-91.

[50] Flahault A, Cadilhac M, Thomas G. Sample size calculation should be performed for design accuracy in diagnostic test studies. J Clin Epidemiol 2005;58:859-62.

[51] Deeks JJ, Altman DG. Sensitivity and specificity and their confidence intervals cannot exceed 100%. BMJ 1999;318:193-4.

[52] Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med 1978;299:926-30.